Israeli Digital Intelligence Firm Cellebrite Cuts Forecasts, Shares Plunge on Wall Street
Israeli digital intelligence firm Cellebrite reported Q2 2026 results below expectations, causing its stock to plunge on Wall Street. The company cut its full-year revenue and ARR forecasts, citing longer sales cycles and slower platform adoption. Concurrently, Cellebrite announced a CEO change, appointing Shivan Ramji to lead the company forward. Despite the setbacks, analysts maintain cautious optimism due to Cellebrite’s strong market position and advanced technology.
הידיעה ב-6 שורות · תקציר של baba
- Cellebrite’s Q2 2026 revenue rose 16% to $131.1 million but missed market expectations.
- The company lowered its full-year ARR forecast to $550-560 million and revenue guidance to $555-561 million.
- CEO Thomas Hogan was replaced by Shivan Ramji to lead the company’s next growth phase.
- Longer sales cycles and slow adoption of platform upgrades caused the financial shortfall.
- Analysts maintain a Moderate Buy rating with a $21.80 price target, implying 43% upside.
- Cellebrite’s federal security certification and AI tools strengthen its competitive edge.
Cellebrite, the digital intelligence company based in Petah Tikva, faced heavy market pressure after releasing its financial results for Q2 2026. Despite reporting a 16% revenue increase to $131.1 million and growth in annual recurring revenue (ARR) to $507.8 million, the figures fell significantly short of market expectations and the company’s earlier guidance. Following the report, Cellebrite’s stock sharply declined at the opening of trading on Wall Street.
The company lowered its full-year ARR forecast to between $550 million and $560 million and trimmed its revenue guidance to $555 million to $561 million. Cellebrite attributed the shortfall to extended sales cycles with law enforcement and security agencies worldwide, as well as slower-than-expected adoption of upgrades to its Inseyets platform. Concurrently, Cellebrite announced a CEO transition: Thomas Hogan will be replaced by Shivan Ramji, who joined the company three months prior as president of products. The company described this as a planned move to place a global technology and product leader at the helm. Hogan stated, "The next chapter for Cellebrite requires a world-class product and technology leader, and Shivan is exactly that leader."
Ramji acknowledged the ARR results were below expectations due to longer sales cycles but emphasized that resetting expectations now provides a more solid foundation for future execution. He also highlighted operational discipline that enabled the company to raise its adjusted annual EBITDA target to $153 million to $159 million.
Wall Street analysts remain cautiously optimistic, maintaining a "Moderate Buy" rating based on five buy recommendations and one hold, with an average price target of $21.80, implying about 43% upside from the current $15.25 share price. Analysts and financial commentators, including The Motley Fool, note Cellebrite’s strong competitive position as a leading digital forensics platform, bolstered by prestigious federal security certification and integration of advanced AI tools like Genesis. The company now faces the challenge of proving its growth potential under new leadership.
אותו אירוע, כפי שכל מערכת דיווחה עליו בנפרד. פתחו כמה דיווחים כדי להשוות מה כל מערכת מדגישה, ומה היא משאירה בחוץ.
אחרים 2
